Balyasny Asset Management LLC Gilead Sciences, Inc. Put Options Transaction History

Balyasny Asset Management LLC

13 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $6.21 Million - $7.84 Million	93,300 Added 288.85%	125,600 $10.5 Million
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $11.3 Million - $13 Million	-178,900 Reduced 84.71%	32,300 $2.22 Million
Q1 2024 May 13, 2024	BUY	$71.58 - $87.29 $780,222 - $951,461	10,900 Added 5.44%	211,200 $15.5 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $2.66 Million - $3.02 Million	36,300 Added 22.13%	200,300 $16.2 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $961,220 - $1.05 Million	13,000 Added 8.61%	164,000 $12.3 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $974,106 - $1.11 Million	-12,600 Reduced 7.7%	151,000 $12.5 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $211,888 - $304,198	3,400 Added 2.12%	163,600 $14 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $7.04 Million - $8.05 Million	118,300 Added 282.34%	160,200 $9.88 Million
Q2 2022 Aug 15, 2022	BUY	$57.72 - $65.01 $2.42 Million - $2.72 Million	41,900 New	41,900 $2.59 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $866,432 - $934,784	-12,800 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $24.6 Million - $26.9 Million	-387,200 Reduced 96.8%	12,800 $881,000
Q2 2020 Aug 14, 2020	SELL	$72.34 - $84.0 $25.3 Million - $29.4 Million	-350,000 Reduced 46.67%	400,000 $30.8 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $54.1 Million - $64.1 Million	750,000	750,000 $60.8 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.